TY - JOUR A1 - Lapa, Constantin A1 - Schreder, Martin A1 - Schirbel, Andreas A1 - Samnick, Samuel A1 - Kortüm, Klaus Martin A1 - Herrmann, Ken A1 - Kropf, Saskia A1 - Einsele, Herrmann A1 - Buck, Andreas K. A1 - Wester, Hans-Jürgen A1 - Knop, Stefan A1 - Lückerath, Katharina T1 - [\(^{68}\)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [\(^{18}\)F]FDG and laboratory values JF - Theranostics N2 - Chemokine (C-X-C motif) receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer including multiple myeloma (MM). Proof-of-concept of CXCR4-directed radionuclide therapy in MM has recently been reported. This study assessed the diagnostic performance of the CXCR4-directed radiotracer [\(^{68}\)Ga]Pentixafor in MM and a potential role for stratifying patients to CXCR4-directed therapies. Thirty-five patients with MM underwent [\(^{68}\)Ga]Pentixafor-PET/CT for evaluation of eligibility for endoradiotherapy. In 19/35 cases, [\(^{18}\)F]FDG-PET/CT for correlation was available. Scans were compared on a patient and on a lesion basis. Tracer uptake was correlated with standard clinical parameters of disease activity. [\(^{68}\)Ga]Pentixafor-PET detected CXCR4-positive disease in 23/35 subjects (66%). CXCR4-positivity at PET was independent from myeloma subtypes, cytogenetics or any serological parameters and turned out as a negative prognostic factor. In the 19 patients in whom a comparison to [\(^{18}\)F]FDG was available, [\(^{68}\)Ga]Pentixafor-PET detected more lesions in 4/19 (21%) subjects, [\(^{18}\)F]FDG proved superior in 7/19 (37%). In the remaining 8/19 (42%) patients, both tracers detected an equal number of lesions. [\(^{18}\)F]FDG-PET positivity correlated with [\(^{68}\)Ga]Pentixafor-PET positivity (p=0.018). [\(^{68}\)Ga]Pentixafor-PET provides further evidence that CXCR4 expression frequently occurs in advanced multiple myeloma, representing a negative prognostic factor and a potential target for myeloma specific treatment. However, selecting patients for CXCR4 directed therapies and prognostic stratification seem to be more relevant clinical applications for this novel imaging modality, rather than diagnostic imaging of myeloma. KW - medicine KW - multiple myeloma KW - FDG KW - molecular imaging KW - CXCR4 KW - PET KW - radionuclide therapy KW - theranostics Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-172106 VL - 7 IS - 1 ER - TY - INPR A1 - Werner, Rudolf A. A1 - Andree, Christian A1 - Javadi, Mehrbod S. A1 - Lapa, Constantin A1 - Buck, Andreas K. A1 - Higuchi, Takahiro A1 - Pomper, Martin G. A1 - Gorin, Michael A. A1 - Rowe, Steven P. A1 - Pienta, Kenneth J. T1 - A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^{18}\)F-DCFPyL PET Imaging T2 - Urology - The Gold Journal N2 - No abstract available. KW - 18F-DCFPyL KW - Virchow Node KW - PSMA-PET KW - Virchow Node KW - Positron Emission Tomography KW - Prostate Cancer KW - PET Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161103 SN - 0090-4295 N1 - This is the accepted manuscript of Rudolf Werner, Christian Andree, Mehrbod S. Javadi, Constantin Lapa, Andreas K. Buck, Takahiro Higuchi, Martin G. Pomper, Michael A.Gorin, Steven P.Rowe, Kenneth J. Pienta: A Voice From the Past: Re-Discovering the Virchow Node with PSMA-Targeted 18F-DCFPyL PET Imaging. Published in Urology 117(2018), p. 18-21. https://doi.org/10.1016/j.urology.2018.03.030 N1 - Die finale Version dieses Artikels steht unter https://doi.org/10.1016/j.urology.2018.03.030 oder https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-164632 open access zur Verfügung. ER - TY - JOUR A1 - Werner, Rudolf A. A1 - Andree, Christian A1 - Javadi, Mehrbod S. A1 - Lapa, Constantin A1 - Buck, Andreas K. A1 - Higuchi, Takahiro A1 - Pomper, Martin G. A1 - Gorin, Michael A. A1 - Rowe, Steven P. A1 - Pienta, Kenneth J. T1 - A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^{18}\)F-DCFPyL PET Imaging JF - Urology - The Gold Journal N2 - No abstract available. KW - 18F-DCFPyL KW - PET KW - PSMA-PET KW - Positron Emission Tomography KW - Prostate Cancer KW - Virchow Node Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164632 SN - 0090-4295 VL - 117 ER - TY - JOUR A1 - Verma, Shwetabh A1 - Kehrer, Tobias A1 - Hesser, Jürgen A1 - Arba Mosquera, Samuel T1 - Analysis of Impact of Humidity and Temperature on Excimer Laser Ablation of Polyethylene Terephthalate, Polymethylmethacrylate, and Porcine Corneal Tissue JF - Lasers in Surgery and Medicine N2 - Background and Objectives To analyze the impact of humidity and temperature on excimer laser ablation of polyethylene terephthalate (PET), polymethylmethacrylate (PMMA) and porcine corneal tissue, and an ablation model to compensate for the temperature and humidity changes on ablation efficiency. Study Design/Materials and Methods The study was conducted using an AMARIS 1050RS (Schwind eye‐tech‐solutions) placed inside a climate chamber at ACTS. Ablations were performed on PET, PMMA, and porcine cornea. The impact of a wide range of temperature (~18°C to ~30°C) and relative humidity (~25% to ~80%) on laser ablation outcomes was tested using nine climate test settings. For porcine eyes, change in defocus was calculated from the difference of post‐ablation to pre‐ablation average keratometry readings. Laser scanning deflectometry was performed to measure refractive change achieved in PMMA. Multiple linear regression was performed using the least square method with predictive factors: temperature, relative humidity, time stamp. Influence of climate settings was modeled for pulse energy, pulse fluence, ablation efficiency on PMMA and porcine cornea tissue. Results Temperature changes did not affect laser pulse energy, pulse fluence (PET), and ablation efficiency (on PMMA or porcine corneal tissue) significantly. Changes in relative humidity were critical and significantly affected laser pulse energy, high fluence and low fluence. The opposite trend was observed between the ablation performance on PMMA and porcine cornea. Conclusions The proposed well‐fitting multi‐linear model can be utilized for compensation of temperature and humidity changes on ablation efficiency. Based on this model, a working window for optimum operation has been found (temperature 18°C to 28°C and relative humidity 25% to 65%) for a maximum deviation of ±2.5% in ablation efficiency in PMMA and porcine corneal tissue. KW - impact of humidity and temperature KW - excimer laser ablation KW - PMMA KW - cornea KW - PET KW - refractive surgery Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-213395 VL - 52 IS - 7 SP - 627 EP - 638 ER - TY - JOUR A1 - Kosmala, Aleksander A1 - Serfling, Sebastian E. A1 - Dreher, Niklas A1 - Lindner, Thomas A1 - Schirbel, Andreas A1 - Lapa, Constantin A1 - Higuchi, Takahiro A1 - Buck, Andreas K. A1 - Weich, Alexander A1 - Werner, Rudolf A. T1 - Associations between normal organs and tumor burden in patients imaged with fibroblast activation protein inhibitor-directed positron emission tomography JF - Cancers N2 - (1) Background: We aimed to quantitatively investigate [\(^{68}\)Ga]Ga-FAPI-04 uptake in normal organs and to assess a relationship with the extent of FAPI-avid tumor burden. (2) Methods: In this single-center retrospective analysis, thirty-four patients with solid cancers underwent a total of 40 [\(^{68}\)Ga]Ga-FAPI-04 PET/CT scans. Mean standardized uptake values (SUV\(_{mean}\)) for normal organs were established by placing volumes of interest (VOIs) in the heart, liver, spleen, pancreas, kidneys, and bone marrow. Total tumor burden was determined by manual segmentation of tumor lesions with increased uptake. For tumor burden, quantitative assessment included maximum SUV (SUV\(_{max}\)), tumor volume (TV), and fractional tumor activity (FTA = TV × SUV\(_{mean}\)). Associations between uptake in normal organs and tumor burden were investigated by applying Spearman's rank correlation coefficient. (3) Results: Median SUV\(_{mean}\) values were 2.15 in the pancreas (range, 1.05–9.91), 1.42 in the right (range, 0.57–3.06) and 1.41 in the left kidney (range, 0.73–2.97), 1.2 in the heart (range, 0.46–2.59), 0.86 in the spleen (range, 0.55–1.58), 0.65 in the liver (range, 0.31–2.11), and 0.57 in the bone marrow (range, 0.26–0.94). We observed a trend towards significance for uptake in the myocardium and tumor-derived SUV\(_{max}\) (ρ = 0.29, p = 0.07) and TV (ρ = −0.30, p = 0.06). No significant correlation was achieved for any of the other organs: SUV\(_{max}\) (ρ ≤ 0.1, p ≥ 0.42), TV (ρ ≤ 0.11, p ≥ 0.43), and FTA (ρ ≤ 0.14, p ≥ 0.38). In a sub-analysis exclusively investigating patients with high tumor burden, significant correlations of myocardial uptake with tumor SUV\(_{max}\) (ρ = 0.44; p = 0.03) and tumor-derived FTA with liver uptake (ρ = 0.47; p = 0.02) were recorded. (4) Conclusions: In this proof-of-concept study, quantification of [\(^{68}\)Ga]Ga-FAPI-04 PET showed no significant correlation between normal organs and tumor burden, except for a trend in the myocardium. Those preliminary findings may trigger future studies to determine possible implications for treatment with radioactive FAP-targeted drugs, as higher tumor load or uptake may not lead to decreased doses in the majority of normal organs. KW - PET KW - [\(^{68}\)Ga]Ga-FAPI KW - theranostics KW - radioligand therapy KW - fibroblast activation protein Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-275154 SN - 2072-6694 VL - 14 IS - 11 ER - TY - CHAP A1 - Werner, Rudolf A1 - Hayakawa, Nobuyuki A1 - Arias-Loza, Paula-Anah A1 - Wakabayashi, Hiroshi A1 - Shinaji, Tetsuya A1 - Lapa, Constantin A1 - Pelzer, Theo A1 - Higuchi, Takahiro T1 - Bildgebung der frühen linksventrikulären Dysfunktion mit ECG-gated F-18-FDG PET in einem Diabetes-Ratten-Modell T2 - Nuklearmedizin N2 - Einleitung: Die linksventrikuläre diastolische Dysfunktion (LVDD) ist bei Diabetikern noch vor Entwicklung einer klinisch apparenten Herzinsuffizienz eines der ersten Anzeichen einer kardialen Beteiligung. Daher soll in dieser Studie untersucht werden, ob die LVDD mit ECG-gated F-18-FDG PET in einem Diabetes-Rattenmodell dargestellt werden kann. Methodik: Es wurden F-18-FDG PET Scans in einem Typ-2-Diabetes Rattenmodell (ZDF fa/fa, n=6) und in ZL Kontrollen (n=6) vorgenommen (Alter, jeweils 13 Wochen). Unter Hyperinsulinemic-Euglycemic Clamp-Technik wurden 37 MBq 18F-FDG über die Schwanzvene appliziert. 15-35 Minuten nach Tracergabe wurden mittels eines Kleintier-PET-Scanners sowie unter EKG-Ableitung PET Scans angefertigt (16 frames/cardiac cycle). Die linksventrikuläre Ejektionsfraktion (EF) und die Peak Füllrate (PFR) wurden mittels einer geeigneten Software (Heart Function View) gemessen, wobei die Software an die Größe des Rattenherzes angepasst wurde. Ergebnisse: Im Alter von 13 Wochen entwickeln ZDF Diabetes-Ratten eine im Vergleich zu Kontrolltieren eine signifikante myokardiale Hypertrophie, bestätigt durch post-mortem Analyse des Herzgewichtes (994±78mg vs. 871±44mg in ZDF Diabetes-Ratten vs. ZL Kontrollen, p<0.01). ECG-gated PET zeigte eine signifikante Abnahme der LV diastolischen PFR (10.4±0.5 vs. 11.8±0.4 EDV/sec in ZDF Diabetes-Ratten vs. ZL Kontrollen, p<0.001), jedoch zeigte sich kein signifikanter Unterschied zwischen LVEF und der Herzfrequenz in den untersuchten ZDF Diabetes-Ratten und Kontrollen (LVEF: 60.0±4.5 vs. 63.7±4.1%, n.s. und HR: 305±25 vs. 323±24 bpm, n.s.). Schlussfolgerung: Im Diabetes-Ratten-Modell kann unter Verwendung eines ECG-gated FDG-PET Protokolls die diastolische Dysfunktion als Parameter der frühen diabetischen Kardiomyopathie nachgewiesen werden. KW - Positronen-Emissions-Tomografie KW - Diabetes KW - diabetische Kardiomyopathie KW - Positronen-Emissions-Tomografie KW - PET KW - EKG KW - ECG KW - ECG-gated Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161396 UR - http://www.nuklearmedizin.de/jahrestagungen/abstr_online2017/print_abstract_pdf.php SN - 0029-5566 N1 - This article is not an exact copy of the original published article in Nuklearmedizin. The definitive publisher-authenticated version of „Bildgebung der frühen linksventrikulären Dysfunktion mit ECG-gated F-18-FDG PET in einem Diabetes-Ratten-Modell. Nuklearmedizin 2017; 56 (Abstract Nr.: V119).“ is available online at http://www.nuklearmedizin.de/jahrestagungen/abstr_online2017/print_abstract_pdf.php VL - 56 IS - 2 PB - Schattauer Verlag ER - TY - JOUR A1 - Griebsch, Nora-Isabell A1 - Kern, Johanna A1 - Hansen, Jonas A1 - Rullmann, Michael A1 - Luthardt, Julia A1 - Helfmeyer, Stephanie A1 - Dekorsy, Franziska J. A1 - Soeder, Marvin A1 - Hankir, Mohammed K. A1 - Zientek, Franziska A1 - Becker, Georg-Alexander A1 - Patt, Marianne A1 - Meyer, Philipp M. A1 - Dietrich, Arne A1 - Blüher, Matthias A1 - Ding, Yu-Shin A1 - Hilbert, Anja A1 - Sabri, Osama A1 - Hesse, Swen T1 - Central serotonin/noradrenaline transporter availability and treatment success in patients with obesity JF - Brain Sciences N2 - Serotonin (5-hydroxytryptamine, 5-HT) as well as noradrenaline (NA) are key modulators of various fundamental brain functions including the control of appetite. While manipulations that alter brain serotoninergic signaling clearly affect body weight, studies implicating 5-HT transporters and NA transporters (5-HTT and NAT, respectively) as a main drug treatment target for human obesity have not been conclusive. The aim of this positron emission tomography (PET) study was to investigate how these central transporters are associated with changes of body weight after 6 months of dietary intervention or Roux-en-Y gastric bypass (RYGB) surgery in order to assess whether 5-HTT as well as NAT availability can predict weight loss and consequently treatment success. The study population consisted of two study cohorts using either the 5-HTT-selective radiotracer [\(^{11}\)C]DASB to measure 5-HTT availability or the NAT-selective radiotracer [\(^{11}\)C]MRB to assess NAT availability. Each group included non-obesity healthy participants, patients with severe obesity (body mass index, BMI, >35 kg/m\(^2\)) following a conservative dietary program (diet) and patients undergoing RYGB surgery within a 6-month follow-up. Overall, changes in BMI were not associated with changes of both 5-HTT and NAT availability, while 5-HTT availability in the dorsal raphe nucleus (DRN) prior to intervention was associated with substantial BMI reduction after RYGB surgery and inversely related with modest BMI reduction after diet. Taken together, the data of our study indicate that 5-HTT and NAT are involved in the pathomechanism of obesity and have the potential to serve as predictors of treatment outcomes. KW - obesity KW - serotonin KW - noradrenaline KW - serotonin transporter KW - noradrenaline transporter KW - Roux-en-Y gastric bypass surgery KW - body mass index (BMI; kg/m\(^2\)) KW - radiotracer KW - PET KW - PET imaging Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-290294 SN - 2076-3425 VL - 12 IS - 11 ER - TY - JOUR A1 - Israel, Ina A1 - Ohsiek, Andrea A1 - Al-Momani, Ehab A1 - Albert-Weissenberger, Christiane A1 - Stetter, Christian A1 - Mencl, Stine A1 - Buck, Andreas K. A1 - Kleinschnitz, Christoph A1 - Samnick, Samuel A1 - Sirén, Anna-Leena T1 - Combined [\(^{18}\)F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice JF - Journal of Neuroinflammation N2 - Background Traumatic brain injury (TBI) is a major cause of death and disability. Neuroinflammation contributes to acute damage after TBI and modulates long-term evolution of degenerative and regenerative responses to injury. The aim of the present study was to evaluate the relationship of microglia activation to trauma severity, brain energy metabolism, and cellular reactions to injury in a mouse closed head injury model using combined in vivo PET imaging, ex vivo autoradiography, and immunohistochemistry. Methods A weight-drop closed head injury model was used to produce a mixed diffuse and focal TBI or a purely diffuse mild TBI (mTBI) in C57BL6 mice. Lesion severity was determined by evaluating histological damage and functional outcome using a standardized neuroscore (NSS), gliosis, and axonal injury by immunohistochemistry. Repeated intra-individual in vivo μPET imaging with the specific 18-kDa translocator protein (TSPO) radioligand [\(^{18}\)F]DPA-714 was performed on day 1, 7, and 16 and [\(^{18}\)F]FDG-μPET imaging for energy metabolism on days 2–5 after trauma using freshly synthesized radiotracers. Immediately after [\(^{18}\)F]DPA-714-μPET imaging on days 7 and 16, cellular identity of the [\(^{18}\)F]DPA-714 uptake was confirmed by exposing freshly cut cryosections to film autoradiography and successive immunostaining with antibodies against the microglia/macrophage marker IBA-1. Results Functional outcome correlated with focal brain lesions, gliosis, and axonal injury. [\(^{18}\)F]DPA-714-μPET showed increased radiotracer uptake in focal brain lesions on days 7 and 16 after TBI and correlated with reduced cerebral [\(^{18}\)F]FDG uptake on days 2–5, with functional outcome and number of IBA-1 positive cells on day 7. In autoradiography, [\(^{18}\)F]DPA-714 uptake co-localized with areas of IBA1-positive staining and correlated strongly with both NSS and the number of IBA1-positive cells, gliosis, and axonal injury. After mTBI, numbers of IBA-1 positive cells with microglial morphology increased in both brain hemispheres; however, uptake of [\(^{18}\)F]DPA-714 was not increased in autoradiography or in μPET imaging. Conclusions [\(^{18}\)F]DPA-714 uptake in μPET/autoradiography correlates with trauma severity, brain metabolic deficits, and microglia activation after closed head TBI. KW - neuroinflammation KW - TBI KW - immunohistochemistry KW - weight drop KW - PET KW - diffuse KW - focal KW - TSPO KW - autoradiography KW - IBA-1 Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-146606 VL - 13 IS - 140 ER - TY - THES A1 - Richter, Dominik T1 - Compressed Sensing zur Filterung und Reduktion der Rekonstruktionszeit in der Positronen-Emissions-Tomographie T1 - Compressed sensing for filtering and reduction of reconstruction time in positron emission tomography N2 - Durch die Verwendung radioaktiver Substanzen mit ihrer schädigenden Wirkung auf den menschlichen Körper besteht in der Positronen-Emissions-Tomographie (PET) ein fortwährendes Interesse an der Reduktion der applizierten Dosis bei gleichbleibender Qualität der Ergebnisse. Zusätzlich ist im Hinblick auf die Wirtschaftlichkeit der Systeme eine Reduktion sowohl der Akquisitions- als auch der Rekonstruktionszeit erstrebenswert. In dieser Arbeit werden zwei Möglichkeiten vorgestellt, diese Ziele durch den Einsatz von Compressed Sensing (CS) zu erreichen. Neben der Entwicklung neuartiger Rekonstruktionsalgorithmen können Filtertechniken eingesetzt werden, um eine qualitative Verbesserung rekonstruierter Bilder zu erzielen. Der Vorteil eines Filters besteht unter anderem darin, dass diese retrospektiv angewandt werden können. Es ist folglich möglich, die Qualität eines Bildes zu überprüfen und lediglich im Bedarfsfall einen Filter einzusetzen. Die Technik des CS war in den letzten Jahren Gegenstand zahlreicher Forschungsarbeiten im Bereich der Bildgebung, insbesondere in der Magnetresonanztomographie und der Computertomographie (CT). Mit CS könnten bildgebende Verfahren wie die CT oder die PET mit weniger Messungen durchgeführt werden, wodurch sich die Messzeit und die Strahlenexposition reduziert. In der molekularen Bildgebung mit der PET ist CS jedoch weitgehend unbekannt. Im ersten Teil dieser Dissertation wird eine Methode vorgestellt, welche CS als Filtertechnik in der PET einsetzt. Den Ausgangspunkt stellt ein vollständiger, analytisch rekonstruierter Datensatz dar. Dieser wird mit einer Reihe unterschiedlicher Abtastmuster retrospektiv unterabgetastet und jeweils erneut, unter Verwendung von CS rekonstruiert. Im rauschfreien Fall würde CS stets das Originalbild liefern. Das überlagerte Rauschen führt jedoch zu Artefakten und einer Verschlechterung des Ergebnisses. CS kann nun einerseits das Rauschen vermindern. Andererseits ist es durch die Mittelung mehrerer unterschiedlicher Rekonstruktionen möglich, die Artefakte zu reduzieren. Auf diesem Weg kann die Bildqualität signifikant verbessert werden. Es konnte gezeigt werden, dass die Technik sowohl für 2D, als auch für 3D Datensätze verwendet werden kann. Die größten qualitativen Verbesserungen werden erzielt, wenn der Datensatz lediglich aus wenigen Ereignissen besteht. In diesem Fall ist die Bildqualität der analytischen Rekonstruktionen extrem schlecht, die Verbesserung durch die Filtertechnik mit CS und die damit verbundene Erhöhung des Signal-Rausch-Verhältnisses jedoch am größten. Bei diesen Datensätzen können die Ergebnisse iterativer Rekonstruktionen übertroffen werden. In der Praxis wäre damit ein Einsatz speziell bei dynamischen oder getriggerten Aufnahmen denkbar. In beiden Fällen basieren die Rekonstruktionen nicht selten auf wenigen Ereignissen. Die resultierenden Bilder sind häufig von schlechter Qualität, womit eine Verbesserung durch Filterung sinnvoll ist. Der zweite Teil dieser Arbeit beschäftigt sich mit der Rohdaten-basierten Triggerung am Kleintier-PET sowie mit dem Einsatz von CS zur Reduktion der Rekonstruktionszeit. Frühere Veröffentlichungen zeigten bereits die Anwendbarkeit Rohdaten-basierter Triggermethoden bei humanen Datensätzen. Im Hinblick auf eine präklinische Anwendung, speziell bei Datensätzen mit dem Fokus auf Mäuseherzen, existieren jedoch nur wenige Studien. In dieser Arbeit wird gezeigt, dass die segmentierte Methode des Massenschwerpunkts (COMseg) eine Technik darstellt, welche die kardiale Triggerung sowohl bei Datensätzen von Ratten, als auch von Mäusen erlaubt. Ein nicht zu unterschätzender Nachteil der COMseg besteht darin, dass vor deren Anwendung die List-Mode Datei in kleine Zeitframes unterteilt und in Sinogramme sortiert werden muss. Auf jedes Sinogramm wird im Anschluss ein Rebinning Algorithmus angewandt. Dies stellt einen enormen Zeitaufwand dar, wodurch sich eine Anwendung bei größeren Studien in der Praxis als schwierig erweist. Ziel der Triggermethoden ist die Gewinnung eines Triggersignals, durch welches beispielsweise der Herzschlag in mehrere Phasen aufgeteilt werden kann. Das Triggersignal hat für gewöhnlich eine dünnbesetzte Repräsentation im Frequenzraum. Dieses Vorwissen ermöglicht den Einsatz von CS. Anstelle des vollständigen Datensatzes wurde lediglich ein Teil der Daten in kleine Zeitframes sortiert und mit der COMseg ausgewertet. Aus diesem unterabgetasteten Datensatz wird mit Hilfe von CS das vollständige Triggersignal rekonstruiert. Die Stärke der Unterabtastung entspricht in etwa dem Faktor der Reduktion der Rekonstruktionszeit. Auf diesem Weg ist es möglich, eine signifikante Beschleunigung zu erzielen. Die Anwendung dieser Technik ist jedoch nicht auf die COMseg beschränkt. Prinzipiell kann das Verfahren bei allen Methoden der Rohdaten-basierten Triggerung angewandt werden, welche es erlauben, die Abtastpunkte des Signals separat zu berechnen. Damit werden Algorithmen interessant, deren Einsatz aufgrund aufwändiger Berechnungen bislang in der Praxis nicht sinnvoll war. Zusammenfassend legen die in dieser Arbeit vorgestellten Daten nahe, dass CS ein neuartiges Werkzeug in der PET darstellen könnte, mit welchem eine Filterung von Bildern sowie eine Reduktion der Rekonstruktionszeit möglich ist. N2 - In positron emission tomography (PET) radioactive substances are used. The exposure to ionizing radiation can cause damage to the human body. Therefore, there is an ongoing interest in reducing the amount of applied dose while keeping the quality of the results. With regard to the cost effectiveness of the systems a reduction of acquisition as well as reconstruction time is desirable. Within this work two possibilities are presented that enable achieving these objectives by using compressed sensing (CS). Filtering methods can be used beside the development of novel reconstruction algorithms to improve the quality of reconstructed images. One advantage of filters is the possibility of retrospective usage. Therewith, the image quality can be evaluated and the filter is solely applied if necessary. Over the past years, CS was the subject of several research activities in the field of imaging techniques, especially in magnetic resonance imaging and x-ray computed tomography (CT). CS could enable imaging modalities such as CT and PET to reconstruct images using fewer measurements, thus reducing scanning time and a patient's exposure to radiation. However, data on applications of CS in the molecular imaging with PET are lacking. The first part of this dissertation describes a method that uses CS as a filter in PET. The initial point is a complete and analytically reconstructed dataset. Several different sampling patterns are applied for retrospective undersampling followed by an reconstruction using CS. In the noise-free case each reconstruction would yield the original image. However, additional noise results in artefacts and in a decline of the result. On the one hand, CS is able to reduce noise. On the other hand, an averaging of several different reconstructions can reduce artefacts. Therewith, the image quality can be improved significantly. It is shown that the method could be applied to 2D as well as to 3D datasets. Best results are obtained when the dataset consists of a few events only. While the quality of analytically reconstructed images is extremely bad, the greatest improvement and therewith the maximum increase of the signal-to-noise ratio is achieved using the CS filter method. Thereby, it is possible to outperform the results of iterative reconstructions. In practice, an application to dynamic or gated acquisitions would be conceivable. Reconstructions at both acquisition modes are often based on few counts. The resulting images are commonly of bad quality, whereby an improvement using a filter is reasonable. The second part of this work deals with raw data based triggering at a small animal PET as well as the application of CS to reduce reconstruction time. Former publications already showed the practicability of raw data based triggering methods at human datasets. However, with regard to preclinical utilisation and especially to datasets that focus mice hearts, there are only few studies available. Within this work it is shown that the segmented centre of mass method (COMseg) enables cardiac gating of datasets of rats as well as mice. When applying the COMseg list-mode data have to be sub-divided into small time frames and sorted to sinograms. Afterwards, a rebinning algorithm is applied to each sinogram. The enormous expenditure of time is a disadvantage that should not be underestimated. In practice, an application to larger studies is difficult thereby. The aim of triggering methods is to yield a triggering signal which enables subdivision e.g. of the heartbeat in several phases. Usually, a triggering signal has a sparse representation in frequency space. This previous knowledge allows the application of CS. Instead of all data only a fraction of the dataset is sorted to small time frames and analysed using the COMseg. CS is used to calculate the complete triggering signal out of the undersampled one. The amount of undersampling corresponds to the reduction factor of reconstruction time. Thereby, a significant acceleration can be achieved. However, the application of this technique is not limited to the COMseg. If a raw data based triggering method calculates each sample individually, CS can be applied. Therefore, algorithms that were not practicable because of long computation times may become interesting. In summary, data of this work suggest that CS could be a novel analysis tool for filtering and reduction of reconstruction time in PET. KW - Komprimierte Abtastung KW - Positronen-Emissions-Tomographie KW - Medizintechnik KW - Filter KW - filtering KW - Compressed Sensing KW - PET Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-106569 ER - TY - JOUR A1 - Üçeyler, Nurcan A1 - Buchholz, Hans-Georg A1 - Kewenig, Susanne A1 - Ament, Stephan-Johann A1 - Birklein, Frank A1 - Schreckenberger, Mathias A1 - Sommer, Claudia T1 - Cortical Binding Potential of Opioid Receptors in Patients With Fibromyalgia Syndrome and Reduced Systemic Interleukin-4 Levels – A Pilot Study JF - Frontiers in Neuroscience N2 - Objective: We investigated cerebral opioid receptor binding potential in patients with fibromyalgia syndrome (FMS) using positron-emission-tomography (PET) and correlated our results with patients’ systemic interleukin-4 (IL-4) gene expression. Methods: In this pilot study, seven FMS patients (1 man, 6 women) agreed to participate in experimental PET scans. All patients underwent neurological examination, were investigated with questionnaires for pain, depression, and FMS symptoms. Additionally, blood for IL-4 gene expression analysis was withdrawn at two time points with a median latency of 1.3 years. Patients were investigated in a PET scanner using the opioid receptor ligand F-18-fluoro-ethyl-diprenorphine ([18F]FEDPN) and results were compared with laboratory normative values. Results: Neurological examination was normal in all FMS patients. Reduced opioid receptor binding was found in mid cingulate cortex compared to healthy controls (p < 0.005). Interestingly, three patients with high systemic IL-4 gene expression had increased opioid receptor binding in the fronto-basal cortex compared to those with low IL-4 gene expression (p < 0.005). Conclusion: Our data give further evidence for a reduction in cortical opioid receptor availability in FMS patients as another potential central nervous system contributor to pain in FMS. KW - fibromyalgia syndrome KW - PET KW - brain KW - opioid KW - IL-4 Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-204457 SN - 1662-453X VL - 14 ER - TY - JOUR A1 - Lapa, Constantin A1 - Herrmann, Ken A1 - Schirbel, Andreas A1 - Hänscheid, Heribert A1 - Lückerath, Katharina A1 - Schottelius, Margret A1 - Kircher, Malte A1 - Werner, Rudolf A. A1 - Schreder, Martin A1 - Samnick, Samuel A1 - Kropf, Saskia A1 - Knop, Stefan A1 - Buck, Andreas K. A1 - Einsele, Hermann A1 - Wester, Hans-Juergen A1 - Kortüm, K. Martin T1 - CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma JF - Theranostics N2 - C-X-C-motif chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. We have recently reported promising first-in-man experience with CXCR4-directed endoradiotherapy (ERT) in multiple myeloma (MM). Eight heavily pretreated MM patients underwent a total of 10 ERT cycles (7 patients with 1 cycle and a single patient with 3 cycles). ERT was administered in combination with chemotherapy and autologous stem cell support. End points were occurrence and timing of adverse events, progression-free and overall survival. ERT was overall well tolerated without any unexpected acute adverse events or changes in vital signs. With absorbed tumor doses >30-70 Gy in intra- or extramedullary lesions, significant anti-myeloma activity was observed with 1 patient achieving complete remission and 5/8 partial remission. Directly after ERT major infectious complications were seen in one patient who died from sepsis 22 days after ERT, another patient with high tumor burden experienced lethal tumor lysis syndrome. Median progression-free survival was 54 days (range, 13-175), median overall survival was 223 days (range, 13-313). During follow-up (6 patients available), one patient died from infectious complications, 2/8 from disease progression, the remaining 3/8 patients are still alive. CXCR4-directed ERT was well-tolerated and exerted anti-myeloma activity even at very advanced stage MM with presence of extramedullary disease. Further assessment of this novel treatment option is highly warranted. KW - medicine KW - multiple myeloma KW - PET KW - CXCR4 KW - theranostics Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-172095 VL - 7 IS - 6 ER - TY - JOUR A1 - Schadt, Fabian A1 - Israel, Ina A1 - Samnick, Samuel T1 - Development and Validation of a Semi-Automated, Preclinical, MRI-Template Based PET Image Data Analysis Tool for Rodents JF - Frontiers in Neuroinformatics N2 - AimIn PET imaging, the different types of radiotracers and accumulations, as well as the diversity of disease patterns, make the analysis of molecular imaging data acquired in vivo challenging. Here, we evaluate and validate a semi-automated MRI template-based data analysis tool that allows preclinical PET images to be aligned to a self-created PET template. Based on the user-defined volume-of-interest (VOI), image data can then be evaluated using three different semi-quantitative parameters: normalized activity, standardized uptake value, and uptake ratio. Materials and MethodsThe nuclear medicine Data Processing Analysis tool (NU_DPA) was implemented in Matlab. Testing and validation of the tool was performed using two types of radiotracers in different kinds of stroke-related brain diseases in rat models. The radiotracers used are 2-[\(^{18}\)F]fluoro-2-deoxyglucose ([\(^{18}\)F]FDG), a metabol\(^{68}\)Ga]Ga-Fucoidan, a target-selective radioligand specifically binding to p-selectin. After manual image import, the NU_DPA tool automatically creates an averaged PET template out of the acquired PET images, to which all PET images are then aligned onto. The added MRI template-based information, resized to the lower PET resolution, defines the VOI and also allows a precise subdivision of the VOI into individual sub-regions. The aligned PET images can then be evaluated semi-quantitatively for all regions defined in the MRI atlas. In addition, a statistical analysis and evaluation of the semi-quantitative parameters can then be performed in the NU_DPA tool. ResultsUsing ischemic stroke data in Wistar rats as an example, the statistical analysis of the tool should be demonstrated. In this [\(^{18}\)F]FDG-PET experiment, three different experimental states were compared: healthy control state, ischemic stroke without electrical stimulation, ischemic stroke with electrical stimulation. Thereby, statistical data evaluation using the NU_DPA tool showed that the glucose metabolism in a photothrombotic lesion can be influenced by electrical stimulation. ConclusionOur NU_DPA tool allows a very flexible data evaluation of small animal PET data in vivo including statistical data evaluation. Using the radiotracers [\(^{18}\)F]FDG and [\(^{68}\)Ga]Ga-Fucoidan, it was shown that the semi-automatic MRI-template based data analysis of the NU_DPA tool is potentially suitable for both metabolic radiotracers as well as target-selective radiotracers. KW - data analysis KW - Matlab KW - MRI KW - PET KW - positron emission tomography KW - preclinical imaging Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-240289 SN - 1662-5196 VL - 15 ER - TY - THES A1 - Herterich, Theresia Margarete Barbara T1 - Die Wertigkeit der PET/CT in der Detektion zervikaler Lymphknotenmetastasen beim oralen Plattenepithelkarzinom T1 - The value of PET/CT in the detection of cervical lymph node metastases in oral squamous cell carcinoma N2 - Das orale Plattenepithelkarzinom zählt zu den häufigen Krebserkrankungen in Deutschland. Das Vorhandensein von zervikalen Lymphknotenmetastasen ist dabei einer der wichtigsten prognostischen Faktoren. Für die Therapieplanung ist eine zuverlässige präoperative Diagnostik unerlässlich. Etablierte bildgebende Stagingverfahren (Sonographie, MRT, CT) orientieren sich allein an morphologischen Kriterien. Die PET/CT verspricht durch die Kombination funktioneller und morphologischer Verfahren die Detektion lymphoregionärer Metastasen. Ein weiterer Vorteil scheint der Nachweis simultaner Zweitmalignome und Fernmetastasen zu sein. 135 Patienten mit einem primären oralen Plattenepithelkarzinom erhielten im Rahmen der präoperativen Staginguntersuchungen eine PET/CT-Untersuchung. Untersucht wurde der korrekte Nachweis (Sensitivität) bzw. Ausschluss (Spezifität) zervikaler Lymphknotenmetastasen sowie die Detektion (Trefferquote) von simultanen Zweitmalignomen durch die PET/CT. Die PET/CT zeigte eine Sensitivität von 82,9 % und eine Spezifität von 84 %. Simultane Zweitmalignome wurden mit einer Trefferquote von 62,5 % durch die PET/CT erkannt. Das diagnostische Potenzial konnte in unserer Studie bestätigt werden. Vergleichende Studien zu den etablierten bildgebenden Verfahren wären wünschenswert. N2 - Oral squamous cell carcinoma is one of the most common cancers in Germany. The presence of cervical lymph node metastases is one of the most important prognostic factors. Reliable preoperative diagnostics are essential for therapy planning. Established imaging staging methods (sonography, MRI, CT) are based solely on morphological criteria. PET/CT promises the detection of lymphoregional metastases by combining functional and morphological methods. Another advantage seems to be the detection of simultaneous secondary malignancies and distant metastases. 135 patients with primary oral squamous cell carcinoma received a PET/CT scan as part of the preoperative staging examinations. The correct detection (sensitivity) or exclusion (specificity) of cervical lymph node metastases as well as the detection (hit rate) of simultaneous second malignancies by PET/CT were investigated. PET/CT showed a sensitivity of 82.9% and a specificity of 84%. Simultaneous second malignancies were detected by PET/CT with a hit rate of 62.5%. The diagnostic potential was confirmed in our study. Comparative studies on the established imaging techniques would be desirable. KW - Emissions-Computertomographie KW - Lymphknotenmetastase KW - PET/CT KW - zervikale Lymphknotenmetastasen KW - orales Plattenepithelkarzinom KW - Mundhöhlenkrebs KW - Mundhöhlenkarzinom KW - PET Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-314021 ER - TY - THES A1 - Omert, Leilah Marie-Luise T1 - Einfluss systemischer Therapie auf die funktionelle Bildgebung des Multiplen Myeloms T1 - Influence of systemic therapy on functional imaging of Multiple Myeloma N2 - Das Multiple Myelom (MM) ist eine maligne hämatologische Erkrankung, die trotz großer Fortschritte in der Therapie immer noch eine schlechte Prognose hat. Bisher ist es nicht möglich, mit einem bildgebenden Verfahren alle Fragen der Diagnostik, der Stadieneinteilung, des Therapiemonitorings und der Evaluation der Prognose des Multiplen Myeloms zu klären. Da es sich beim Multiplen Myelom aber um eine stark heterogene Erkrankung handelt, die eine frühzeitige individuelle Therapie erfordert, ist es unbedingt nötig Verfahren zu entwickeln, die eine spezifische Charakterisierung der Erkrankung bei jedem einzelnen Patienten ermöglichen. In der vorliegenden Arbeit wurden die MM-Zelllinien INA-6, MM.1S und OPM-2 mit dem Proteasominhibitor MLN9708 behandelt. Behandelte und unbehandelte Zellen wurden mit dem Standardtracer 2-[18F]-Fluoro-2-Desoxy-D-Glukose (18F-FDG) oder dem in der Anwendung beim Multiplen Myelom neuen Aminosäuretracer [11C]-Methionin (11C-MET) inkubiert und die Aufnahme der Tracer zu bestimmten Zeitpunkten gemessen. Des Weiteren wurde die Ausprägung biologischer Merkmale der MM-Pathogenese bei behandelten und unbehandelten Zellen untersucht. Anschließend wurde ermittelt, ob ein Zusammenhang zwischen der Höhe der Traceraufnahme und der Ausprägung biologischer Merkmale der MM-Pathogenese bei behandelten und unbehandelten Zellen besteht. Hierdurch soll geklärt werden, ob 11C-MET besser zur Diagnostik, dem Therapiemonitoring und der Evaluation der Prognose des Multiplen Myeloms geeignet ist als der Standardtracer 18F-FDG. Es zeigte sich eine signifikant höhere 11C-MET-Aufnahme sowohl unbehandelter als auch behandelter Zellen im Vergleich zu 18F-FDG. Außerdem war eine Unterscheidung zwischen behandelten und unbehandelten Zellen mit 11C-MET besser möglich als mit 18F-FDG. Zwischen Traceraufnahme und biologischen Merkmalen der MM-Pathogenese, wie Proliferation, Expression von intrazellulären Leichtketten, CXCR4 und CD138, ergaben sich für behandelte und unbehandelte Zellen variable Zusammenhänge. Die Ergebnisse legen nahe, dass 11C-MET besser zur Diagnostik und zum Therapiemonitoring des Multiplen Myeloms geeignet ist als der Standardtracer 18F-FDG. Ob 11C-MET auch zur Stadieneinteilung und zur Evaluation der Prognose des Multiplen Myeloms besser geeignet ist als 18F-FDG, muss in weiteren Studien untersucht werden. N2 - Despite new therapies Multiple Myeloma (MM) remains a hematologic malignancy with poor prognosis. Because of marked disease heterogeneity outcomes are extremely variable. The role of functional imaging, such as positron emission tomography for diagnosis, therapy monitoring, staging and prognostication is being investigated for a few years. This study evaluated the radiotracers 11C-Methionine (paraprotein-biosynthesis) and 18F-FDG (glucose-utilization) for diagnosis, therapy monitoring, staging and outcome prediction of MM. Influence of proteasome-inhibitor MLN9708 (Ixazomib) on radiotracer-uptake of different MM cell-lines was analyzed and related to tumor-biology. Both untreated and treated MM cells significantly took up more 11C-Methionine than 18F-FDG. Discrimination of treated and untreated cells was only possible with 11C-Methionine. Correlations between tracer uptake and tumor biology were variable for both tracers. These results suggest that 11C-Methionine is superior to 18F-FDG in diagnosis and therapy monitoring of MM. The suitability of 11C-Methionine for staging and prognostication has to be evaluated in further studies. KW - Multiples Myelom KW - Bildgebung KW - PET Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-154793 ER - TY - THES A1 - Becker, Kilian T1 - Entwicklung eines 3D-Ganzkörper-Ultraschalls an Kleintieren für morphologische Bildgebung, Volumetrie und Bildfusion mit PET T1 - Development of a 3D whole-body ultrasound in small animals for morphological imaging, volumetry and image fusion with PET N2 - Einleitung: Ultraschall wird seit mehr als 50 Jahren in der Medizin eingesetzt und ist mittlerweile ein unverzichtbares diagnostisches Verfahren, es erlaubt eine nicht-invasive Darstellung der Morphologie und Funktion von Organen in Echtzeit. In der Kleintierbildgebung dominieren bisher zur morphologischen Bildgebung Computertomographie (CT) und Magnetresonanztomographie (MRT). Daher wurde in der vorliegenden Arbeit die Idee entwickelt, die morphologischen Informationen des 3D-Ultraschalls (3D-US) für Untersuchungen an Kleintieren zu verwenden, außerdem sollten Methoden zur multimodalen Bildgebung und Bildfusion von 3D-US und Kleintier-Positronenemissionstomographie (PET) entwickelt werden. Der Vorteil des Ultraschalls gegenüber dem Kleintier-CT liegt in der fehlenden Strahlenbelastung und der guten Verfügbarkeit, was besonders für Verlaufsstudien von Interesse ist. Methoden und Ergebnisse: Zur Bildoptimierung wurde ein Fadenphantom entwickelt, welches aufgrund der feinen Strukturen die qualitative als auch quantitative Bestimmung der Auflösung ermöglicht. Die Vorarbeiten am Fadenphantom konnten exzellent die Probleme des 3D-Ultraschalls mit der achsenabhängigen Auflösung zeigen und ermöglichten eine schnelle Beurteilung der Bildqualität. Hier bestehen Einsatzmöglichkeiten in der Bewertung verschiedener Ultraschallgeräte bezüglich der Tauglichkeit für 3D-Datenaquisition. Zur reproduzierbaren Lagerung von Mäusen wurde eine Schallkopfführung ein sowohl für 3D-US als auch Kleintier-PET kompatibler Tierhalter entwickelt. Die Maus lag zur Untersuchung im angewärmten Wasserbad auf dem Tierhalter fixiert, mit Inhalationsanästhesie und Sauerstoff über eine Atemmaske versorgt. Der Zeitaufwand für eine 3D-US-Untersuchung betrug für die Akquisition etwa eine Minute. Die generierten Ultraschalldatensätze waren von guter Qualität, Strukturen wie Leber, Nieren, Blase, Wirbelsäule und Lunge konnten selbst bei kleinen Mäusen von unter 20 Gramm Körpergewicht gut dargestellt werden. Zur Validierung des 3D-Ultraschalls wurde das Volumen verschiedener Organe und Tumore bestimmt und mit dem Goldstandard verglichen. Um die Koregistrierung mit der Kleintier-PET zu ermöglichen, wurden auf dem Tierhalter drei „fiducial markers“ angebracht, die Position und Orientierung eindeutig definieren. Die Kleintier-PET-Untersuchungen wurden nach standardisierten Protokollen durchgeführt. Die anschließende Bildfusion erfolgte mittels der frei verfügbaren Software "Amide". Diskussion: Mit dem in dieser Arbeit beschriebenen Verfahren ist eine standardisierte Gewinnung von 3D-US-Datensätzen an Kleintieren möglich; zusätzlich konnte die Machbarkeit der Bildfusion mit PET-Datensätzen gezeigt werden. Der Einsatz des 3D-Ultraschalls in longitudinalen Studien, zum Beispiel zur Beurteilung der Tumorprogression, ist vorstellbar. Die Zuverlässigkeit der volumetrischen Berechnungen ist für größere Organvolumina gut, bei kleineren Volumina besteht noch Optimierungsbedarf. Weitere Verbesserungen könnten durch den Einsatz von speziellen Schallköpfen und höheren Schallfrequenzen erzielt werden. N2 - Introduction: Ultrasound has been used for more than 50 years in medicine and has become a indispensable diagnostic tool, it allows a non-invasive imaging of the morphology and function of organs in real time. Small animal morphological imaging is now dominated by CT and MRI. For present study the idea to use morphological information of the 3D-ultrasound for examination of small animals was developed, these data should be used for image fusion of 3D ultrasound and small-animal PET. The advantage of ultrasound compared to the small-animal CT is the lack of radiation exposure and the good availability, which is especially for longitudinal studies of interest. Methods and Results: For image enhancement, a thread phantom was developed, fine structures facilitate qualitative and quantitative analysis of spatial resolution. Preliminary work on the thread phantom was excellent for investigate problems of 3D ultrasound with the axis-dependent resolution. There are potential applications for evaluating different ultrasonic devices in their suitability for 3D data acquisition. For the reproducible bedding of mice a guide bar for ultrasound transducer and a compatible holder for 3D-US and PET was developed. The mouse was bedded in the heated water bath fixed to the holder, applied inhalation anesthesia and oxygen through a breathing mask. The time required for a 3D ultrasound examination was for the acquisition of about one minute. The generated ultrasound data sets were of good quality, structures such as liver, kidney, bladder, spine and lungs were even in the case of small mice of 20 gram well represented. For validation of the 3D ultrasound volumes of various organs and tumors were determined and compared with gold standard. To allow coregistration with the microPET, three "fiducial markers" were attached to define the position and orientation. PET studies were performed according to standardized protocols. The subsequent image fusion was performed using the software "amide”. Discussion: In this study a standardized procedure for 3D-US of small animals was developed, in addition, the feasibility of image fusion with PET data sets was shown. The use of 3D ultrasound in longitudinal studies, for example, to assess tumor progression, is conceivable. The reliability of the volumetric calculations is good for large organ volumes, with smaller volumes, there is still need for improvement. Further improvements could be achieved through the use of special transducers and higher ultrasound frequencies. KW - Ultraschalldiagnostik KW - Nuklearmedizin KW - Würzburg / Klinik und Poliklinik für Nuklearmedizin KW - Molekulare Bildgebung KW - 3D-Ultraschall KW - dreidimensionaler Ultraschall KW - PET KW - Positronenemissionstomographie KW - Bildfusion KW - 3D ultrasound KW - three-dimensional ultrasound KW - PET KW - positron emission tomography KW - image fusion Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-55916 ER - TY - THES A1 - Schadt, Fabian T1 - Entwicklung und erste Validierung eines innovativen Analysen-Tools für präklinische Bewertungen von PET-Radiopharmazeutika zur \(in\) \(vivo\) Untersuchungen neurologischer Erkrankungen T1 - Development and initial validation of an innovative analytical tool for preclinical evaluations of PET radiopharmaceuticals for \(in\) \(vivo\) investigations of neurological disease N2 - Die präklinische Forschung stellt den ersten wichtigen Meilenstein in der Klärung und Untersuchung klinisch-relevanter Erkrankungen dar. Darüber hinaus unterstützt die präklinische Forschung erheblich die Entwicklung von Therapien. Die Kleintier-Positronenemissionstomographie (µ-PET) spielt dabei eine wichtige Rolle, da sie in der Lage ist, funktionelle, physiologische und biochemische Prozesse in vivo darzustellen und zu quantifizieren. Trotz diverser etablierter PET-Datenauswertungs-Programme bleibt die Analyse von in vivo akquirierten Bilddaten aufgrund der Vielzahl an medizinischen Fragestellungen, der Komplexität der Krankheitsbilder, sowie der Etablierung neuer Radiotracer weiterhin eine große Herausforderung in der Medizin. Ziel dieser Doktorarbeit ist es daher, ein geeignetes, brauchbares Auswertungstool für eine einfache und effiziente Analyse von akquirierten µ-PET-Daten zu entwickeln und zu etablieren, welches das Spektrum bereits vorhandener Programme erweitert. Das entwickelte nuklearmedizinische Datenverarbeitungs-Analyseprogramm (engl. nuclear medicine data processing analysis tool, NU_DPA) wurde in Matlab implementiert und anhand dreier präklinischer Versuchs- bzw. Testreihen erprobt und etabliert. Bei den Datenreihen handelt es sich um µ-PET-Datensätze verschiedener Schlaganfall-Rattenhirnmodelle unter Verwendung folgender Radiotracer. Zum einen die im Gehirn homogen akkumulierende 2-[18F]Fluor-2-desoxy-glukose ([18F]FDG) zum anderen das spezifisch an P-Selektin anreichernde [68Ga]Fucoidan. Das NU_DPA umfasst die automatische Selektion des Zielvolumens (volume-of-interest, VOI) aus dem vollständigen PET-Bild und die anschließende Ausrichtung des VOI mit Hilfe eines PET-Templates (gemittelter PET-Datensatz). Dieses PET Template wird aus den eigenen akquirierten PET-Daten erstellt. Durch das Einbinden eines geeigneten anatomischen MRT-Atlas‘ (anpassbar) können die ausgerichteten PET-Daten einzelnen, Atlas-spezifischen Teilregionen zugeordnet werden. Eine solche Subklassifikation des VOI erlaubt eine genauere Betrachtung und Auswertung der Radiotracer-Akkumulation. Des Weiteren bietet NU_DPA die Möglichkeit einer semiquantitativen Auswertung der PET-Bilddaten anhand von drei unterschiedlichen Parametern, der normalisierten Aktivität, dem Standardized Uptake Value und der Uptake Ratio. Durch die Matlab-integrierten Statistik-Algorithmen ist zusätzlich eine Möglichkeit der statistischen Auswertung der zuvor berechneten Parameter gegeben. Das NU_DPA-Programm stellt somit ein semi-automatisiertes Datenauswertungs-Programm dar, das sowohl die Registrierung als auch die semiquantitative Auswertung von PET-Bilddaten innerhalb einer Versuchsreihe ermöglicht und bereits erfolgreich für die Radiotracer [18F]FDG und [68Ga]Fucoidan in Tiermodellen getestet wurde. Nach derzeitigem Kenntnisstand ist kein Datenauswertungs-Programm bekannt, das PET-Bilddaten unter Verwendung des hinzugefügten Atlas‘ semi-automatisiert analysieren kann und potenziell für homogene und Target-spezifisch akkumulierende Radiotracer geeignet ist. N2 - Preclinical research represents the first important milestone in the clarification and investigation of clinically relevant diseases. In addition, preclinical research significantly supports the development of therapies. Small animal positron emission tomography (µ-PET) plays an important role in this context, as it is able to image and quantify functional, physiological and biochemical processes in vivo. Despite various established µ-PET data analysis programs, the analysis of in vivo acquired image data remains a major challenge in medicine due to the multitude of medical questions, the complexity of disease patterns, and the establishment of new radiotracers. Therefore, the aim of this PhD thesis is to develop and establish a suitable, usable evaluation tool for a simple and efficient analysis of acquired µ-PET data, which extends the spectrum of already existing programs. The developed nuclear medicine data processing analysis tool (NU_DPA) was implemented in Matlab and tested and established on the basis of three preclinical experimental or test series. The data series are µ-PET datasets of different stroke rat brain models using the following radiotracers: 2-[18F]fluoro-2-deoxy-glucose ([18F]FDG), which accumulates homogeneously in the brain and [68Ga]fucoidan, which specifically accumulates at p-selectin. The NU_DPA involves automatic segmentation of a volume-of-interest (VOI) from the full PET image and the subsequent alignment of the VOI using a PET template (averaged PET dataset). This PET template is created from the own acquired PET data. By embedding a suitable anatomical MR atlas (customizable), the aligned PET data can be assigned to individual atlas-specific sub-regions. Such a sub-classification of the VOI allows a more detailed analysis and evaluation of the radiotracer accumulation. Furthermore, NU_DPA offers the possibility of a semi-quantitative evaluation of the PET image data based on three different parameters, the normalized activity, the standardized uptake value and the uptake ratio. The Matlab-integrated statistical algorithms provide an additional option for statistical evaluation of the previously calculated semi-quantitative parameters. The NU_DPA program thus represents a semi-automatic data evaluation program that enables both the registration and the semi-quantitative evaluation of PET image data within a series of experiments and it has already been successfully tested for the radiotracers [18F]FDG and [68Ga]fucoidan in animal models. To the best of our current knowledge, there is no known data analysis program that can semi-automatically analyze PET image data using the added atlas and is potentially suitable for homogeneous and target-specific accumulating radiotracers. KW - PET KW - Präklinische Bildgebung Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-247499 ER - TY - JOUR A1 - Werner, Rudolf A1 - Wakabyashi, Hiroshi A1 - Chen, Xinyu A1 - Hirano, Mitsuru A1 - Shinaji, Tetsuya A1 - Lapa, Constantin A1 - Rowe, Steven A1 - Javadi, Mehrbod A1 - Higuchi, Takahiro T1 - Functional renal imaging with \(^{18}\)F-FDS PET in rat models of renal disorders JF - Journal of Nuclear Medicine N2 - Background: Precise regional quantitative assessment of renal function is limited with conventional \(^{99m}\)Tc-labeled renal radiotracers. A recent study reported that the positron emission tomography (PET) radiotracer 2-deoxy-2-(\(^{18}\)F-fluorosorbitol (\(^{18}\)F-FDS) has ideal pharmacokinetics for functional renal imaging. Furthermore, (\(^{18}\)F-FDS is available via simple reduction from routinely used 2-deoxy-2-(\(^{18}\)F-fluoro-D-glucose ((\(^{18}\)F-FDG). We aimed to further investigate the potential of (\(^{18}\)F-FDS PET as a functional renal imaging agent using rat models of kidney diseases. Methods: Two different rat models of renal impairment were investigated: Glycerol induced acute renal failure (ARF) by intramuscular administration of glycerol in hind legs and unilateral ureteral obstruction (UUO) by ligation of the left ureter. 24h after these treatments, dynamic 30 min 18F-FDS PET data were acquired using a dedicated small animal PET system. Urine 18F-FDS radioactivity 30 min after radiotracer injection was measured together with co-injected \(^{99m}\)Tc-diethylenetriaminepentaacetic acid (\(^{99m}\)Tc-DTPA) urine activity. Results: Dynamic PET imaging demonstrated rapid (\(^{18}\)F-FDS accumulation in the renal cortex and rapid radiotracer excretion via kidneys in control healthy rats. On the other hand, significantly delayed renal radiotracer uptake (continuous slow uptake) was observed in ARF rats and UUO-treated kidneys. Measured urine radiotracer concentrations of (\(^{18}\)F-FDS and \(^{99m}\)Tc-DTPA were well correlated (R=0.84, P<0.05). Conclusions: (\(^{18}\)F-FDS PET demonstrated favorable kinetics for functional renal imaging in rat models of kidney diseases. Advantages of high spatiotemporal resolution of PET imaging and simple tracer production could potentially complement or replace conventional renal scintigraphy in select cases and significantly improve the diagnostic performance of renal functional imaging. KW - unilateral ureteral obstruction KW - Nierenfunktionsstörung KW - Positronen-Emissions-Tomografie KW - 18F-FDS KW - 99mTc-DTPA KW - PET KW - renal failure KW - Glomerular filtration Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161279 SN - 0161-5505 N1 - This research was originally published in JNM. Rudolf A. Werner, Hiroshi Wakabayashi, Xinyu Chen, Mitsuru Hirano, Tetsuya Shinaji, Constantin Lapa, Steven P. Rowe, Mehrbod S. Javadi and Takahiro Higuchi. Functional renal imaging with 18F-FDS PET in rat models of renal disorders. J Nucl Med. May 1, 2018;vol. 59 no. 5: 828-832. © SNMMI. ER - TY - JOUR A1 - Serfling, Sebastian E. A1 - Lapa, Constantin A1 - Dreher, Niklas A1 - Hartrampf, Philipp E. A1 - Rowe, Steven P. A1 - Higuchi, Takahiro A1 - Schirbel, Andreas A1 - Weich, Alexander A1 - Hahner, Stefanie A1 - Fassnacht, Martin A1 - Buck, Andreas K. A1 - Werner, Rudolf A. T1 - Impact of tumor burden on normal organ distribution in patients imaged with CXCR4-targeted [\(^{68}\)Ga]Ga-PentixaFor PET/CT JF - Molecular Imaging and Biology N2 - Background CXCR4-directed positron emission tomography/computed tomography (PET/CT) has been used as a diagnostic tool in patients with solid tumors. We aimed to determine a potential correlation between tumor burden and radiotracer accumulation in normal organs. Methods Ninety patients with histologically proven solid cancers underwent CXCR4-targeted [\(^{68}\)Ga]Ga-PentixaFor PET/CT. Volumes of interest (VOIs) were placed in normal organs (heart, liver, spleen, bone marrow, and kidneys) and tumor lesions. Mean standardized uptake values (SUV\(_{mean}\)) for normal organs were determined. For CXCR4-positive tumor burden, maximum SUV (SUV\(_{max}\)), tumor volume (TV), and fractional tumor activity (FTA, defined as SUV\(_{mean}\) x TV), were calculated. We used a Spearman's rank correlation coefficient (ρ) to derive correlative indices between normal organ uptake and tumor burden. Results Median SUV\(_{mean}\) in unaffected organs was 5.2 for the spleen (range, 2.44 – 10.55), 3.27 for the kidneys (range, 1.52 – 17.4), followed by bone marrow (1.76, range, 0.84 – 3.98), heart (1.66, range, 0.88 – 2.89), and liver (1.28, range, 0.73 – 2.45). No significant correlation between SUV\(_{max}\) in tumor lesions (ρ ≤ 0.189, P ≥ 0.07), TV (ρ ≥ -0.204, P ≥ 0.06) or FTA (ρ ≥ -0.142, P ≥ 0.18) with the investigated organs was found. Conclusions In patients with solid tumors imaged with [\(^{68}\)Ga]Ga-PentixaFor PET/CT, no relevant tumor sink effect was noted. This observation may be of relevance for therapies with radioactive and non-radioactive CXCR4-directed drugs, as with increasing tumor burden, the dose to normal organs may remain unchanged. KW - CXCR4 KW - C-X-C motif chemokine receptor 4 KW - PET KW - [68Ga]PentixaFor KW - [177Lu]/[90Y]PentixaTher KW - theranostics KW - endoradiotherapy Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324622 VL - 24 IS - 4 ER - TY - INPR A1 - Werner, Rudolf A. A1 - Bundschuh, Ralph A. A1 - Bundschuh, Lena A1 - Javadi, Mehrbod S. A1 - Leal, Jeffrey P. A1 - Higuchi, Takahiro A1 - Pienta, Kenneth J. A1 - Buck, Andreas K. A1 - Pomper, Martin G. A1 - Gorin, Michael A. A1 - Lapa, Constantin A1 - Rowe, Steven P. T1 - Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on \(^{18}\)F-DCFPyL PET/CT Imaging T2 - Journal of Nuclear Medicine N2 - Objectives: Recently, the standardized reporting and data system for prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging studies, termed PSMA-RADS version 1.0, was introduced. We aimed to determine the interobserver agreement for applying PSMA-RADS to imaging interpretation of 18F-DCFPyL PET examinations in a prospective setting mimicking the typical clinical work-flow at a prostate cancer referral center. Methods: Four readers (two experienced readers (ER, > 3 years of PSMA-targeted PET interpretation experience) and two inexperienced readers (IR, < 1 year of experience)), who had all read the initial publication on PSMA-RADS 1.0, assessed 50 18F-DCFPyL PET/computed tomography (CT) studies independently. Per scan, a maximum of 5 target lesions were selected by the observers and a PSMA-RADS score for every target lesion was recorded. No specific pre-existing conditions were placed on the selection of the target lesions, although PSMA-RADS 1.0 suggests that readers focus on the most highly avid or largest lesions. An overall scan impression based on PSMA-RADS was indicated and interobserver agreement rates on a target lesion-based, on an organ-based, and on an overall PSMA-RADS score-based level were computed. Results: The number of target lesions identified by each observer were as follows: ER 1, 123; ER 2, 134; IR 1, 123; and IR 2, 120. Among those selected target lesions, 125 were chosen by at least two individual observers (all four readers selected the same target lesion in 58/125 (46.4%) instances, three readers in 40/125 (32%) and two observers in 27/125 (21.6%) instances). The interobserver agreement for PSMA-RADS scoring among identical target lesions was good (intraclass correlation coefficient (ICC) for four, three and two identical target lesions, ≥0.60, respectively). For lymph nodes, an excellent interobserver agreement was derived (ICC=0.79). The interobserver agreement for an overall scan impression based on PSMA-RADS was also excellent (ICC=0.84), with a significant difference for ER (ICC=0.97) vs. IR (ICC=0.74, P=0.005). Conclusions: PSMA-RADS demonstrates a high concordance rate in this study, even among readers with different levels of experience. This suggests that PSMA-RADS can be effectively used for communication with clinicians and can be implemented in the collection of data for large prospective trials. KW - 18F-DCFPyL KW - Positronen-Emissions-Tomografie KW - PSMA-RADS KW - interreader KW - interobserver KW - PSMA KW - prostate cancer KW - RADS KW - reporting and data system KW - PET Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-167788 SN - 0161-5505 N1 - This research was originally published in JNM. Rudolf A. Werner, Ralph A. Bundschuh, Lena Bundschuh, Mehrbod S. Javadi, Jeffrey P. Leal, Takahiro Higuchi, Kenneth J. Pienta, Andreas K. Buck, Martin G. Pomper, Michael A. Gorin, Constantin Lapa and Steven P. Rowe. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging. J Nucl Med 2018;59:1857-1864 © SNMMI. ER - TY - CHAP A1 - Werner, Rudolf A1 - Chen, Xinyu A1 - Lapa, Constantin A1 - Robinson, Simon A1 - Higuchi, Takahiro T1 - Intracellular behavior of the novel sympathetic nerve agent \(^{18}\)F-LMI1195 T2 - Journal of Nuclear Cardiology N2 - No abstract available. KW - Herz KW - PET KW - sympathetic nerve KW - autonomic nervous system KW - 18F-LMI1195 KW - positron emission tomography KW - heart KW - cardiac Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161137 SN - 1071-3581 N1 - This is a post-peer-review, pre-copyedit version of an article published in J Nucl Cardiol. ISSN: 1071-3581. Supplement (2017) Aug;24;4: 1461-1496. The final authenticated version is available online at: http://dx.doi.org/10.1007/s12350-017-0984-y VL - 24 IS - 4 Supplement (2017) Aug ER -